DDInter1510 DDInter1435
Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030.[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Praziquantel {u} (Compound) resembles {v} (Compound) Palonosetron
Praziquantel {u} (Compound) binds {v} (Gene) CYP3A5
Praziquantel {u} (Compound) upregulates {v} (Gene) PAK6
Praziquantel {u} (Compound) downregulates {v} (Gene) ATP6V1D
Praziquantel {u} (Compound) causes {v} (Side Effect) Decreased appetite
Praziquantel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Praziquantel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isavuconazonium
Praziquantel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Praziquantel {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Praziquantel {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Praziquantel (Compound) resembles Palonosetron (Compound)
Praziquantel (Compound) binds CYP3A5 (Gene)
Praziquantel (Compound) upregulates PAK6 (Gene)
Praziquantel (Compound) downregulates ATP6V1D (Gene)
Praziquantel (Compound) causes Decreased appetite (Side Effect)
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Praziquantel may lead to a major life threatening interaction when taken with Lumacaftor
Praziquantel may lead to a major life threatening interaction when taken with Rifabutin